CHTH · As filed with the SEC
CNL Healthcare Properties cash flow statement, by fiscal year
The statement as CNL Healthcare Properties presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD thousands
| USD thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Operating activities: | ||||
| Net loss | (14,418) | (25,664) | (412) | (22,866) |
| Net loss from discontinued operations | — | 0 | 0 | (10) |
| Net loss from continuing operations | — | (25,664) | (412) | (22,856) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||
| Depreciation and amortization | 50,689 | 51,234 | 54,242 | 50,417 |
| Amortization of loan costs | 5,221 | 2,440 | 2,769 | 2,193 |
| Amortization of premium for debt investments | 0 | (17) | (42) | (42) |
| Amortization of discounts | 0 | (760) | (151) | — |
| Straight-line rent adjustments | 1,701 | 1,737 | 1,209 | 1,231 |
| Deferred income tax expense | — | 0 | 0 | 3,632 |
| Loss on extinguishment of debt | 0 | 131 | 28 | 43 |
| Impairment provision | — | 0 | 0 | 9,790 |
| Write-off of deferred rent and lease related costs | — | — | 0 | 0 |
| Gain on sale of real estate | 0 | 0 | (6,282) | 0 |
| Gain on change of control of a joint venture | 0 | 0 | (8,376) | — |
| Other non-cash operating activities | 1,043 | 4,140 | 984 | 1,304 |
| Changes in operating assets and liabilities: | ||||
| Other assets | (3,411) | (1,933) | (640) | (1,326) |
| Deferred rent and lease incentives | — | 0 | 0 | (250) |
| Accounts payable and accrued liabilities | (2,449) | 1,143 | 76 | 4,718 |
| Other liabilities | 1,879 | (392) | 450 | (2,108) |
| Due to related parties | 35 | (105) | (9) | (374) |
| Net cash flows provided by operating activities – continuing operations | — | 31,954 | 43,846 | 46,372 |
| Straight-line rent adjustments | — | — | — | 0 |
| Loss on extinguishment of debt | — | — | — | 0 |
| Write-off of deferred rent and lease related costs | — | — | — | 0 |
| Gain on sale of real estate | — | — | — | 0 |
| Other assets | — | — | — | 14,000 |
| Accounts payable and accrued liabilities | — | — | — | (8,000) |
| Other liabilities | — | — | — | (3,000) |
| Other operating activities | — | — | — | (3,000) |
| Net cash flows used in operating activities – discontinued operations | — | 0 | 0 | (10) |
| Net cash flows provided by operating activities | 40,290 | 31,954 | 43,846 | 46,362 |
| Investing activities: | ||||
| Acquisition of joint venture interest, net of cash acquired | — | — | (1,134) | — |
| Acquisition of joint venture interest, net of cash acquired | 0 | 0 | — | — |
| Net proceeds from sale of real estate | 0 | 0 | 36,655 | 0 |
| Capital expenditures | (16,142) | (15,868) | (17,789) | (14,186) |
| Purchase of held-to-maturity securities | 0 | (4,880) | (24,209) | — |
| Proceeds from maturity of short-term securities | 0 | 30,000 | — | — |
| Other investing activities | 0 | 0 | 291 | 35 |
| Net cash provided by (used in) investing activities – continuing operations | — | 9,252 | (6,186) | (14,151) |
| Net proceeds from sale of real estate | — | 0 | 0 | 7,402 |
| Capital expenditures | — | — | — | 0 |
| Other investing activities | — | — | — | 0 |
| Net cash provided by investing activities – discontinued operations | — | 0 | 0 | 7,402 |
| Net cash (used in) provided by investing activities | (16,142) | 9,252 | (6,186) | (6,749) |
| Financing activities: | ||||
| Distributions to stockholders | (17,812) | (17,813) | (17,814) | (35,627) |
| Redemptions of common stock | — | — | — | 0 |
| Draws under credit facilities | 16,000 | 190,770 | 45,000 | 238,000 |
| Proceeds from mortgage and other notes payable | — | — | — | 0 |
| Repayments on credit facilities | (10,000) | (190,770) | 0 | 0 |
| Principal payments on mortgages and other notes payable | (20,968) | (25,284) | (46,294) | (247,753) |
| Purchase of interest rate caps | (100) | (3,285) | — | — |
| Payment of loan costs | (15) | (12,449) | (328) | (2,404) |
| Purchase of noncontrolling interests | (1,528) | — | — | — |
| Distributions to noncontrolling interests | 0 | (100) | (2,215) | — |
| Other financing activities | 0 | 39 | (116) | (159) |
| Net cash flows used in financing activities | (34,423) | (58,892) | (21,767) | (47,943) |
| Net (decrease) increase in cash and restricted cash | (10,275) | (17,686) | 15,893 | (8,330) |
| Cash and restricted cash at beginning of period | 55,888 | 73,574 | 57,681 | 66,011 |
| Cash and restricted cash at end of period | 45,613 | 55,888 | 73,574 | 57,681 |
| Supplemental disclosure of cash flow information: | ||||
| Cash paid for interest, net | 41,209 | 34,900 | 17,020 | 17,615 |
| Cash paid for taxes, net | 823 | 687 | 801 | 690 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.